Thus, given the controversies, lack of specificity, and inability to accurately identify patients at high risk of developing aggressive PCa using PSA screening, there is an urgent need for (1) a deeper understanding of the genomic differences between indolent and aggressive PCas and (2) discovery of clinically actionable molecular markers dysregulated by genetic alterations, which could be used to improve patient stratification by identifying men at high risk of developing aggressive tumors that could be prioritized for treatment. Here, KLK3 is linked to posterior cortical atrophy.